Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The company was founded on March 5, 2018 and is headquartered in Kefar Sava, Israel.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 11,050,000,000 ordinary shares represented by 2,210,000 American Depositary Shares at a purchase price of $5.00 per ADS and pre-funded warrants to purchase 5,750,000,000 ordinary shares represented by 1,150,000 American Depositary Shares at a per pre-funded warrant price of $4.9999 (with each ADS and pre-funded warrant accompanied by an ordinary warrant) for an aggregate gross proceeds of $16.8 million.

Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering

Endo affiliate, Paladin Labs, will commercialize Quoin's lead asset for Netherton Syndrome in Canada Endo affiliate, Paladin Labs, will commercialize Quoin's lead asset for Netherton Syndrome in Canada

Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

Endo International

The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN , July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) for the development, registration, supply, commercialization and distribution of QRX003 on an exclusive basis in Canada. If the product is approved, Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities in Canada.

Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 Versus Vehicle Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 Versus Vehicle

Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study

QNRX stock is nearly doubling after the company sought permission to cancel an announcement of share sales.  The post Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?

Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?

Akebia Therapeutics

Ricebran Technologies

Shift Technologies

Penny stocks under $1 to watch. The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 4 To Watch Under $1

ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on June 10, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on Nasdaq.

Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Exclusive agreement establishes a major outlet for Quoin's products in the Asian market Exclusive agreement establishes a major outlet for Quoin's products in the Asian market

Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China

As the rare disease drug development landscape continues to evolve, Quoin (NASDAQ: QNRX) is focused on staying ahead of its competitors.New York, New York--(Newsfile Corp. - June 14, 2022) - PCG Digital -- The life sciences industry has always been dynamic; a collective of organizations from small and agile to large multinationals with one common feature, a need to be creative enough to adapt and change course as challenges arise. Social, political and economic influences, the regulatory environment and competition from deep-pocketed Big Pharma all present substantial challenges for small biotech companies. The overarching question...

Quoin Pharmaceuticals: Strategically Building For Future Success

The FDA has accepted Quoin Pharmaceuticals Inc's (NASDAQ: QNRX) Investigational New Drug (IND) application for its licensed formulation, which uses Skinvisible Inc's (OTC: SKVI) Invisicare drug delivery technology.  The topical formulation "QRX003".

Why Are Quoin Pharma Shares Trading Higher Today?

Amarin Corporation Plc

Clovis Oncology

Mullen Automotive

Penny stocks to watch The post Penny Stocks To Buy Now? 4 To Watch With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now? 4 To Watch With Big News

Quoin Pharmaceuticals (QNRX) is developing a potential treatment for a patient population in desperate need. We spoke with CEO, Dr. Michael Myers, to find out more about Netherton Syndrome, a rare and devastating genetic disease.New York, New York--(Newsfile Corp. - May 17, 2022) - PCG Digital -- People with rare diseases face severe limitations, debilitating discomfort, and a very uncertain future. Children are especially vulnerable: 3 out of 10 children born with a rare disease do not live to see their 5th birthday. Rare diseases can be challenging to diagnose, but even once a diagnosis is reached, effective treatment options can be even more elusive.

Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome

Quoin Pharmaceuticals (NASDAQ: QNRX) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate clinical testing for its Investigational New Drug application for QRX003. QRX003 is Quoin's investigational product for.

Why Quoin Pharmaceuticals Stock Is Trading Higher

Quoin Will Initiate Clinical Testing in 1H 2022 Quoin Will Initiate Clinical Testing in 1H 2022

Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome

As company (QNRX) gains strength, Chief Operating Officer, Denise Carter, talks about what's next for QuoinNew York, New York--(Newsfile Corp. - March 24, 2022) - PCG Digital -- Netherton Syndrome (NS) is a rare and devastating skin disease that is estimated to affect between 2,000 and 4,000 people in the United States, and a similar number in Europe. It has no cure, and current treatment primarily involves the use of over-the-counter moisturizers which provide only minor symptomatic relief.Quoin Pharmaceuticals' (NASDAQ: QNRX) investigational product for NS, QRX003, may become the first...

Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024

Quoin Anticipates Initiating Clinical Testing in Q2 2022 Quoin Anticipates Initiating Clinical Testing in Q2 2022

Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome

First Step in Development Process of QRX003 for the EU First Step in Development Process of QRX003 for the EU

Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome

ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has extended its exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe (“CCE”), for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.

Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome

ASHBURN, Va., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with Neopharm Medical Supplies, an exclusive distributor for leading medical and pharma manufacturers in Israel, for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome

New York, New York--(Newsfile Corp. - February 8, 2022) - PCG Digital - Emerging specialty pharma company, Quoin Pharmaceuticals (NASDAQ: QNRX), coined the phrase 'Rare diseases are only rare if you don't live with one' to emphasize its own mission: to deliver unique solutions to help treat rare disorders that have no approved treatments or cures.

Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy

Creative Medical Technology Holdings

Diversified Healthcare Trust

IMAC Holdings Inc

SeaChange International

What are the best penny stocks to buy today? The post Best Reddit Penny Stocks To Buy Now?

Best Reddit Penny Stocks To Buy Now? 5 Trending Stocks To Watch Today

Aridis Pharmaceuticals

Reliance Global Group

Making a penny stocks watchlist today? Check these three out The post Best Penny Stocks to Buy as 2021 Ends?

Best Penny Stocks to Buy as 2021 Ends? 3 to Watch Right Now

Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) has entered into an exclusive distribution agreement with Orpharm LLC for QRX003, for Netherton Syndrome, a rare genetic disease. Under the agreement terms, Orpharm gains exclusive rights to commercialize QRX003 in Russia and CIS.

Why Are Quoin Pharma Shares Trading Lower On Wednesday?

New York, New York--(Newsfile Corp. - December 14, 2021) - PCG Digital -- Drug development is complex, lengthy and expensive, and not without its risks. Bringing a drug to market takes years, with costs quickly running into hundreds of millions of dollars, and no promise of success at the end of it all. Rare and orphan indications provide an R&D 'sweet spot' for biopharmaceutical companies pursuing drug development. Drugs for rare diseases have a high...

The R&D Sweet Spot: Quoin Pharmaceuticals Delivering Value-Based Drug Development Through Rare and Orphan Disease Therapeutics

New York, New York--(Newsfile Corp. - November 16, 2021) - PCG Digital -- Following a successful merger, one firm is developing and commercializing therapies for rare skin conditions. Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide.Key TakeawaysQuoin recently completed a successful merger with Cellect Biotechnology Ltd. and is now trading on the Nasdaq Capital Market (NASDAQ: QNRX).The company has a...

News for Quoin Pharmaceuticals Ltd Stock (QNRX)